Integrated BioPharma (INBP) stock price, revenue, and financials

Integrated BioPharma market cap is $260.7 m, and annual revenue was $49.98 m in FY 2019

$260.7 M

INBP Mkt cap, 18-Oct-2018

$50 M

Integrated BioPharma Revenue FY, 2019
Integrated BioPharma Gross profit (FY, 2019)6.2 M
Integrated BioPharma Gross profit margin (FY, 2019), %12.4%
Integrated BioPharma Net income (FY, 2019)1.7 M
Integrated BioPharma EBIT (FY, 2019)2.7 M
Integrated BioPharma Cash, 30-Jun-2019475 K

Integrated BioPharma Revenue

Integrated BioPharma revenue was $49.98 m in FY, 2019

Embed Graph

Integrated BioPharma Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

33.7m37.5m42.2m47.0m43.7m50.0m

Revenue growth, %

11%13%

Cost of goods sold

28.8m33.1m36.7m40.3m38.7m43.8m

Gross profit

4.9m4.4m5.5m6.7m5.0m6.2m

Gross profit Margin, %

14%12%13%14%11%12%

General and administrative expense

3.5m3.5m3.4m3.5m3.3m3.5m

Operating expense total

3.5m3.5m3.4m3.5m3.3m3.5m

EBIT

1.4m933.0k2.1m3.2m1.7m2.7m

EBIT margin, %

4%2%5%7%4%5%

Interest expense

964.0k979.0k953.0k911.0k926.0k630.0k

Pre tax profit

220.0k869.0k1.2m1.9m1.0m2.0m

Net Income

131.0k735.0k958.0k2.3m679.0k1.7m

Integrated BioPharma Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

451.0k71.0k395.0k132.0k228.0k475.0k

Accounts Receivable

2.2m2.6m3.1m4.0m3.8m4.4m

Inventories

5.7m5.8m7.8m7.6m7.7m8.8m

Current Assets

9.2m9.3m12.1m12.6m12.2m14.1m

PP&E

1.2m1.4m1.6m1.6m1.7m1.8m

Total Assets

11.6m11.6m14.1m15.2m14.6m19.8m

Accounts Payable

5.6m5.1m5.5m4.2m4.2m3.9m

Short-term debt

588.0k719.0k

Current Liabilities

11.7m11.9m11.8m11.2m16.2m12.4m

Long-term debt

Total Debt

588.0k719.0k

Total Liabilities

21.7m20.9m22.4m21.1m19.8m17.9m

Additional Paid-in Capital

44.6m44.7m44.7m44.8m44.8m50.2m

Retained Earnings

(54.7m)(53.9m)(53.0m)(50.6m)(50.0m)(48.3m)

Total Equity

(10.2m)(9.3m)(8.3m)(5.9m)(5.2m)1.9m

Financial Leverage

-1.1 x-1.2 x-1.7 x-2.6 x-2.8 x10.5 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

480.0k135.0k184.0k294.0k48.0k354.0k84.0k60.0k450.0k92.0k66.0k196.0k284.0k54.0k62.0k365.0k45.0k431.0k

Accounts Receivable

2.0m2.3m1.9m2.3m3.4m2.8m2.8m4.0m3.6m3.8m4.4m2.7m2.7m4.6m3.2m3.4m4.5m5.0m

Inventories

6.5m5.8m4.7m7.0m6.8m5.9m6.1m7.0m6.8m8.1m7.8m7.9m7.0m8.1m8.6m9.6m11.5m10.5m

Current Assets

10.0m9.2m7.8m10.5m11.1m10.0m9.8m11.9m11.7m12.7m13.1m11.6m10.6m13.2m12.3m13.7m16.5m16.4m

PP&E

1.2m1.2m1.2m1.5m1.5m1.4m1.4m1.5m1.5m1.5m1.5m1.7m1.6m1.7m1.7m1.6m1.8m1.8m

Total Assets

12.6m11.8m10.3m13.1m13.7m12.4m12.1m14.2m14.1m14.6m15.0m13.6m13.4m15.6m14.6m19.7m22.6m22.2m

Accounts Payable

5.6m5.0m4.9m6.4m5.9m5.8m6.0m6.5m6.1m4.8m5.6m4.7m3.7m5.6m4.9m6.0m7.2m6.0m

Short-term debt

869.0k598.0k596.0k754.0k707.0k713.0k824.0k959.0k946.0k1.0m

Current Liabilities

12.1m11.1m10.2m12.9m13.4m12.5m12.1m14.4m12.3m11.8m12.0m10.5m9.9m12.5m11.3m12.6m15.5m14.4m

Total Debt

869.0k598.0k596.0k754.0k707.0k713.0k824.0k959.0k946.0k1.0m

Total Liabilities

22.6m21.4m20.4m22.9m21.1m23.3m23.2m22.3m22.7m21.1m19.5m22.1m20.7m19.5m22.1m20.8m

Additional Paid-in Capital

44.6m44.6m44.6m44.6m44.6m44.6m44.7m44.7m44.7m44.7m44.7m44.7m44.8m44.8m44.8m50.0m50.1m50.1m

Retained Earnings

(54.5m)(54.1m)(54.6m)(54.3m)(53.7m)(53.8m)(53.7m)(53.8m)(53.7m)(52.3m)(52.4m)(52.2m)(50.8m)(51.2m)(50.8m)(49.8m)(49.5m)(48.6m)

Total Equity

(10.0m)(9.6m)(10.0m)(9.8m)(9.2m)(9.3m)(9.1m)(9.1m)(9.1m)(7.7m)(7.7m)(7.5m)(6.1m)(6.4m)(6.1m)195.0k466.0k1.4m

Debt to Equity Ratio

-0.1 x-0.1 x

Debt to Assets Ratio

0.1 x0.1 x

Financial Leverage

-1.3 x-1.2 x-1 x-1.3 x-1.5 x-1.3 x-1.3 x-1.6 x-1.6 x-1.9 x-1.9 x-1.8 x-2.2 x-2.4 x-2.4 x101.1 x48.4 x16 x

Integrated BioPharma Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

131.0k735.0k958.0k2.3m679.0k1.7m

Depreciation and Amortization

390.0k405.0k351.0k393.0k348.0k321.0k

Accounts Receivable

248.0k(440.0k)(527.0k)(884.0k)182.0k(593.0k)

Inventories

733.0k(79.0k)(2.0m)111.0k(96.0k)(1.1m)

Accounts Payable

(247.0k)(488.0k)727.0k(1.3m)7.0k(329.0k)

Cash From Operating Activities

1.9m(113.0k)(594.0k)397.0k1.2m328.0k

Purchases of PP&E

(182.0k)(235.0k)(109.0k)(327.0k)(247.0k)(414.0k)

Cash From Investing Activities

(182.0k)(156.0k)(107.0k)(327.0k)(242.0k)(422.0k)

Cash From Financing Activities

(1.3m)(111.0k)1.0m(333.0k)(830.0k)341.0k

Interest Paid

716.0k714.0k745.0k884.0k800.0k629.0k

Income Taxes Paid

7.0k158.0k168.0k366.0k221.0k264.0k

Integrated BioPharma Ratios

USDY, 2019

Revenue/Employee

390.4k

Financial Leverage

10.5 x